CT-ADP Point-of-Care Assay Predicts 30-Day Paravalvular Aortic Regurgitation and Bleeding Events following Transcatheter Aortic Valve Replacement

Abstract

Background Paravalvular aortic regurgitation (PVAR) remains a frequent postprocedural concern following transcatheter aortic valve replacement (TAVR). Persistence of flow turbulence results in the cleavage of high-molecular-weight von Willebrand multimers, primary haemostasis dysfunction and may favour bleedings. Recent data have emphasized the value of a point-of-care measure of von Willebrand factor–dependent platelet function (closure time [CT] adenosine diphosphate [ADP]) in the monitoring of immediate PVAR. This study examined whether CT-ADP could detect PVAR at 30 days and bleeding complications following TAVR.

Methods CT-ADP was assessed at baseline and the day after the procedure. At 30 days, significant PVAR was defined as a circumferential extent of regurgitation more than 10% by transthoracic echocardiography. Events at follow-up were assessed according to the Valve Academic Research Consortium-2 consensus classification.

Results Significant PVAR was diagnosed in 44 out of 219 patients (20.1%). Important reduction of CT-ADP could be found in patients without PVAR, contrasting with the lack of CT-ADP improvement in significant PVAR patients. By multivariate analysis, CT-ADP > 180 seconds (hazard ratio [HR]: 5.1, 95% confidence interval [CI]: 2.5–10.6; p < 0.001) and a self-expandable valve were the sole independent predictors of 30-day PVAR. At follow-up, postprocedural CT-ADP >180 seconds was identified as an independent predictor of major/life-threatening bleeding (HR: 1.7, 95% CI [1.0–3.1]; p = 0.049). Major/life-threatening bleedings were at their highest levels in patients with postprocedural CT-ADP > 180 seconds (35.2 vs. 18.8%; p = 0.013).

Conclusion Postprocedural CT-ADP > 180 seconds is an independent predictor of significant PVAR 30 days after TAVR and may independently contribute to major/life-threatening bleedings.

Keywords

bleeding - aortic regurgitation - paravalvular leak - von Willebrand syndrome

• References

• 1 Van Belle E, Juthier F, Susen S. , et al; FRANCE 2 Investigators. Postprocedural aortic regurgitation in balloon-expandable and self-expandable transcatheter aortic valve replacement procedures: analysis of predictors and impact on long-term mortality: insights from the FRANCE2 registry. Circulation 2014; 129 (13) 1415-1427
• 2 Jerez-Valero M, Urena M, Webb JG. , et al. Clinical impact of aortic regurgitation after transcatheter aortic valve replacement: insights into the degree and acuteness of presentation. JACC Cardiovasc Interv 2014; 7 (09) 1022-1032
• 3 Pibarot P, Hahn RT, Weissman NJ, Monaghan MJ. Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. JACC Cardiovasc Imaging 2015; 8 (03) 340-360
• 4 Hahn RT, Pibarot P, Weissman NJ, Rodriguez L, Jaber WA. Assessment of paravalvular aortic regurgitation after transcatheter aortic valve replacement: intra-core laboratory variability. J Am Soc Echocardiogr 2015; 28 (04) 415-422
• 5 Van Belle E, Rauch A, Vincentelli A. , et al. Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions. Circ Res 2015; 116 (07) 1193-1201
• 6 Van Belle E, Rauch A, Vincent F. , et al. Von Willebrand factor multimers during transcatheter aortic-valve replacement. N Engl J Med 2016; 375 (04) 335-344
• 7 Vincentelli A, Susen S, Le Tourneau T. , et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349 (04) 343-349
• 8 Blackshear JL, McRee CW, Safford RE. , et al. von Willebrand factor abnormalities and Heyde syndrome in dysfunctional heart valve prostheses. JAMA Cardiol 2016; 1 (02) 198-204
• 9 Caspar T, Jesel L, Desprez D. , et al. Effects of transcutaneous aortic valve implantation on aortic valve disease-related hemostatic disorders involving von Willebrand factor. Can J Cardiol 2015; 31 (06) 738-743
• 10 Spangenberg T, Budde U, Schewel D. , et al. Treatment of acquired von Willebrand syndrome in aortic stenosis with transcatheter aortic valve replacement. JACC Cardiovasc Interv 2015; 8 (05) 692-700
• 11 Rauch A, Caron C, Vincent F. , et al. A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis. Thromb Haemost 2016; 115 (05) 950-959
• 12 Morel O, El Ghannudi S, Hess S. , et al. The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight. Thromb Haemost 2012; 108 (02) 338-348
• 13 Bander J, Elmariah S, Aledort LM. , et al. Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty. Thromb Haemost 2012; 108 (01) 86-93
• 14 Casonato A, Sponga S, Pontara E. , et al. von Willebrand factor abnormalities in aortic valve stenosis: pathophysiology and impact on bleeding. Thromb Haemost 2011; 106 (01) 58-66
• 15 Auffret V, Lefevre T, Van Belle E. , et al; FRANCE TAVI Investigators. Temporal trends in transcatheter aortic valve replacement in France: FRANCE 2 to FRANCE TAVI. J Am Coll Cardiol 2017; 70 (01) 42-55
• 16 Abdel-Wahab M, Comberg T, Büttner HJ. , et al; Segeberg-Krozingen TAVI Registry. Aortic regurgitation after transcatheter aortic valve implantation with balloon- and self-expandable prostheses: a pooled analysis from a 2-center experience. JACC Cardiovasc Interv 2014; 7 (03) 284-292
• 17 Gilard M, Eltchaninoff H, Donzeau-Gouge P. , et al; FRANCE 2 Investigators. Late outcomes of transcatheter aortic valve replacement in high-risk patients: the FRANCE-2 registry. J Am Coll Cardiol 2016; 68 (15) 1637-1647
• 18 Généreux P, Cohen DJ, Mack M. , et al. Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. J Am Coll Cardiol 2014; 64 (24) 2605-2615
• 19 Généreux P, Poulin F, Leon MB. von Willebrand disease after TAVR: the missing link?. JACC Cardiovasc Interv 2015; 8 (09) 1266
• 20 Piccolo R, Pilgrim T, Franzone A. , et al. Frequency, timing, and impact of access-site and non-access-site bleeding on mortality among patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv 2017; 10 (14) 1436-1446
• 21 Nijenhuis VJ, Bennaghmouch N, van Kuijk JP, Capodanno D, ten Berg JM. Antithrombotic treatment in patients undergoing transcatheter aortic valve implantation (TAVI). Thromb Haemost 2015; 113 (04) 674-685